IRONWOOD PHARMACEUTICALS, INC. Additional Paid in Capital, Common Stock
IRONWOOD PHARMACEUTICALS, INC. (IRWD) had Additional Paid in Capital, Common Stock of $1.42 billion as of 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Balance Sheet › Equity › Equity, Including Portion Attributable to Noncontrolling Interest › Equity, Attributable to Parent
us-gaap:AdditionalPaidInCapitalCommonStock · last filed 2026-08-06
- 2026-06-30: Additional Paid in Capital, Common Stock $1.42B.
- 2026-03-31: Additional Paid in Capital, Common Stock $1.42B.
- 2025-12-31: Additional Paid in Capital, Common Stock $1.41B.
- 2025-09-30: Additional Paid in Capital, Common Stock $1.41B.
| Period end | Additional Paid in Capital, Common Stock |
|---|---|
| 2026-06-30 | $1.42B 10-Q · filed 2026-08-06 |
| 2026-03-31 | $1.42B 10-Q · filed 2026-05-07 |
| 2025-12-31 | $1.41B 10-Q · filed 2026-08-06 |
| 2025-09-30 | $1.41B 10-Q · filed 2025-11-10 |
| 2025-06-30 | $1.41B 10-Q · filed 2025-08-11 |
| 2025-03-31 | $1.40B 10-Q · filed 2025-05-12 |
| 2024-12-31 | $1.40B 10-K · filed 2026-02-26 |
| 2024-09-30 | $1.39B 10-Q · filed 2024-11-07 |
| 2024-06-30 | $1.38B 10-Q · filed 2024-08-08 |
| 2024-03-31 | $1.37B 10-Q · filed 2024-05-09 |
| 2023-12-31 | $1.36B 10-K · filed 2025-03-31 |
| 2023-09-30 | $1.37B 10-Q · filed 2023-11-09 |
| 2023-06-30 | $1.37B 10-Q · filed 2023-08-09 |
| 2023-03-31 | $1.36B 10-Q · filed 2023-05-04 |
| 2022-12-31 | $1.35B 10-K · filed 2024-02-16 |
| 2022-09-30 | $1.34B 10-Q · filed 2022-11-03 |
| 2022-06-30 | $1.33B 10-Q · filed 2022-08-04 |
| 2022-03-31 | $1.35B 10-Q · filed 2022-05-05 |
| 2021-12-31 | $1.54B 10-K · filed 2025-03-31 |
| 2021-09-30 | $1.56B 10-Q · filed 2021-11-04 |
| 2021-06-30 | $1.55B 10-Q · filed 2021-08-05 |
| 2021-03-31 | $1.54B 10-Q · filed 2021-05-06 |
| 2020-12-31 | $1.53B 10-K · filed 2022-02-18 |
| 2020-09-30 | $1.52B 10-Q · filed 2020-11-05 |
| 2020-06-30 | $1.51B 10-Q · filed 2020-08-06 |
| 2020-03-31 | $1.50B 10-Q · filed 2020-05-06 |
| 2019-12-31 | $1.48B 10-K · filed 2021-02-17 |
| 2019-09-30 | $1.47B 10-Q · filed 2019-10-31 |
| 2019-06-30 | $1.42B 10-Q · filed 2019-07-30 |
| 2019-03-31 | $1.41B 10-Q · filed 2019-05-02 |
| 2018-12-31 | $1.39B 10-K · filed 2020-02-13 |
| 2018-09-30 | $1.38B 10-Q · filed 2018-11-06 |
| 2018-06-30 | $1.36B 10-Q · filed 2018-08-06 |
| 2018-03-31 | $1.33B 10-Q · filed 2018-05-04 |
| 2017-12-31 | $1.32B 10-K · filed 2019-02-25 |
| 2017-09-30 | $1.30B 10-Q · filed 2017-11-02 |
| 2017-06-30 | $1.29B 10-Q · filed 2017-08-03 |
| 2017-03-31 | $1.27B 10-Q · filed 2017-05-08 |
| 2016-12-31 | $1.26B 10-K · filed 2018-02-22 |
| 2016-09-30 | $1.24B 10-Q · filed 2016-11-07 |
| 2016-06-30 | $1.23B 10-Q · filed 2016-08-08 |
| 2016-03-31 | $1.21B 10-Q · filed 2016-05-10 |
| 2015-12-31 | $1.21B 10-K · filed 2017-02-22 |
| 2015-09-30 | $1.20B 10-Q · filed 2015-11-05 |
| 2015-06-30 | $1.19B 10-Q · filed 2015-08-07 |
| 2015-03-31 | $1.07B 10-Q · filed 2015-05-06 |
| 2014-12-31 | $1.06B 10-K · filed 2016-02-19 |
| 2014-09-30 | $1.04B 10-Q · filed 2014-11-05 |
| 2014-06-30 | $1.03B 10-Q · filed 2014-08-05 |
| 2014-03-31 | $1.02B 10-Q · filed 2014-04-29 |
| 2013-12-31 | $815.93M 10-K · filed 2015-02-18 |
| 2013-09-30 | $809.91M 10-Q · filed 2013-10-28 |
| 2013-06-30 | $803.36M 10-Q · filed 2013-08-08 |
| 2013-03-31 | $657.32M 10-Q · filed 2013-04-23 |
| 2012-12-31 | $648.96M 10-K · filed 2014-02-07 |
| 2012-09-30 | $643.15M 10-Q · filed 2012-11-06 |
| 2012-06-30 | $637.48M 10-Q · filed 2012-08-07 |
| 2012-03-31 | $632.03M 10-Q · filed 2012-05-10 |
| 2011-12-31 | $542.14M 10-K · filed 2013-02-21 |
| 2011-09-30 | $538.24M 10-Q · filed 2011-11-09 |
| 2011-06-30 | $534.75M 10-Q · filed 2011-08-12 |
| 2010-12-31 | $526.99M 10-K · filed 2012-02-29 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Nuvectis Pharma, Inc. (NVCT) | United States | $0.705B | -17.53 |
| Climb Bio, Inc. (CLYM) | United States | $0.683B | -13.03 |
| Verastem, Inc. (VSTM) | United States | $0.706B | -1.71 |
| ZEVRA THERAPEUTICS, INC. (ZVRA) | United States | $0.668B | 14.61 |
| COLLEGIUM PHARMACEUTICAL, INC (COLL) | United States | $0.737B | 24.57 |
| BlossomHill Therapeutics, Inc. (BLSM) | United States | $0.647B | |
| Faeth Therapeutics, Inc. (FTH) | United States | $0.750B | |
| Shattuck Labs, Inc. (STTK) | United States | $0.634B | -13.30 |
| Neurogene Inc. (NGNE) | $0.625B | -4.46 | |
| Design Therapeutics, Inc. (DSGN) | United States | $0.766B | -12.78 |